Patents by Inventor Adrian Vivian Sinton Hill
Adrian Vivian Sinton Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11857640Abstract: Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.Type: GrantFiled: April 15, 2020Date of Patent: January 2, 2024Assignee: Oxford University Innovation LimitedInventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
-
Publication number: 20230173050Abstract: An immunogenic composition comprising: a) one or more Plasmodium-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in FIG. 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in FIG. 2 or FIG. 3; and/or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are Plasmodium-derived ETRAMPs and/or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.Type: ApplicationFiled: May 11, 2020Publication date: June 8, 2023Applicants: OXFORD UNIVERSITY INNOVATION LIMITED, FUNDÃÇAO OSWALDO CRUZInventors: Adrian Vivian Sinton Hill, Paulo Jorge Gonçalves de BETTENCOURT, Alexandra Jane SPENCER, Nicola Maria Nathalie TERNETTE, Ahmed Mahmoud Ahmed Ahmed SALMAN, Caroline Furtado JUNQUEIRA, Ricardo Tostes GAZZINELLI, Camila Raquel Rodrigues BARBOSA
-
Publication number: 20200360533Abstract: Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.Type: ApplicationFiled: April 15, 2020Publication date: November 19, 2020Inventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
-
Patent number: 10646587Abstract: Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.Type: GrantFiled: June 20, 2017Date of Patent: May 12, 2020Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
-
Patent number: 10053497Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.Type: GrantFiled: June 5, 2003Date of Patent: August 21, 2018Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Publication number: 20180028635Abstract: The present invention provides a particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen, and wherein the particle comprises no, or substantially no, free hepatitis B surface antigen protein, and uses thereof.Type: ApplicationFiled: October 18, 2017Publication date: February 1, 2018Applicant: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Katharine Alice Collins, Sarah Catharine Gilbert, Adrian Vivian Sinton Hill
-
Publication number: 20180000966Abstract: Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.Type: ApplicationFiled: June 20, 2017Publication date: January 4, 2018Inventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
-
Patent number: 9821046Abstract: The present invention provides a particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen, and wherein the particle comprises no, or substantially no, free hepatitis B surface antigen protein, and uses thereof.Type: GrantFiled: January 21, 2014Date of Patent: November 21, 2017Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Katharine Alice Collins, Sarah Catharine Gilbert, Adrian Vivian Sinton Hill
-
Patent number: 9714435Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors. In particular, the present invention provides an adenovirus vector comprising a capsid derived from chimpanzee adenovirus AdY25, wherein said capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest.Type: GrantFiled: May 25, 2012Date of Patent: July 25, 2017Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
-
Publication number: 20160304582Abstract: The invention relates to the use of a molecular adjuvant to generate an improved immune response in a host. Over recent years extensive research and development has been undertaken in the development of “vectored vaccines” which can be used as vaccine delivery systems. Vectored vaccines include DNA vectors and recombinant viral and bacterial vectors, which are engineered to express an antigen of interest. The invention provides a nucleic acid construct encoding a protein fusion between an antigen and an invariant chain molecule.Type: ApplicationFiled: December 3, 2014Publication date: October 20, 2016Applicant: ISIS INNOVATION LIMITEDInventors: Adrian Vivian Sinton Hill, Alexandra J. Spencer, Benedict R. Halbroth, Matthew G. Cottingham
-
Publication number: 20160144011Abstract: The present invention provides a particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen, and wherein the particle comprises no, or substantially no, free hepatitis B surface antigen protein, and uses thereof.Type: ApplicationFiled: January 21, 2014Publication date: May 26, 2016Inventors: Katharine Alice COLLINS, Sarah Catharine GILBERT, Adrian Vivian Sinton HILL
-
Patent number: 9181311Abstract: There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections.Type: GrantFiled: October 15, 2010Date of Patent: November 10, 2015Assignees: Isis Innovation Limited, Imaxio SAInventors: Alexandra Jane Spencer, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Fergal Hill
-
Publication number: 20150044766Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors. In particular, the present invention provides an adenovirus vector comprising a capsid derived from chimpanzee adenovirus AdY25, wherein said capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest.Type: ApplicationFiled: May 25, 2012Publication date: February 12, 2015Inventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
-
Patent number: 8329144Abstract: A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence 62PQPELPY68 (SEQ ID NO:1), and fusion proteins, pharmaceutical compositions, and kits comprising the same, are provided herewith. Also provided are methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising contacting a sample from the individual with a peptide analogue and determining in vitro whether T cells in the sample recognize the peptide analogue.Type: GrantFiled: November 3, 2006Date of Patent: December 11, 2012Assignee: Isis Innovation LimitedInventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Publication number: 20120282290Abstract: There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections.Type: ApplicationFiled: October 15, 2010Publication date: November 8, 2012Applicants: IMAXIO SA, ISIS INNOVATION LIMITEDInventors: Alexandra Jane Spencer, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Fergal Hill
-
Patent number: 7888460Abstract: A food comprising a mutant gliadin protein that comprises at least one mutation in the epitope 62PQPQLPY68 (SEQ ID NO:6), wherein the mutation decreases the ability of the epitope to induce a T cell response, or a fragment of the mutant gliadin protein wherein the fragment is at least 15 amino acids long and comprises the mutated 62PQPQLPY68 (SEQ ID NO:6) is provided herein.Type: GrantFiled: November 3, 2006Date of Patent: February 15, 2011Assignee: Isis Innovation LimitedInventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Publication number: 20100322896Abstract: This invention relates to the use of a molecular adjuvant to generate an immune response in a host. In particular, the molecular adjuvant may be a TLR signalling pathway component, a co-stimulatory molecule, an NKG2D ligand, IL- or IL-15.Type: ApplicationFiled: October 7, 2008Publication date: December 23, 2010Inventors: Adrian Vivian Sinton Hill, David Wyllie, Karen Colbjorn Larsen, Alexandra Jane Spencer, Matthew Cottingham, Sarah Gilbert
-
Publication number: 20080175971Abstract: A food comprising a mutant gliadin protein that comprises at least one mutation in the epitope 62PQPQLPY68 (SEQ ID NO:6), wherein the mutation decreases the ability of the epitope to induce a T cell response, or a fragment of the mutant gliadin protein wherein the fragment is at least 15 amino acids long and comprises the mutated 62PQPQLPY68 (SEQ ID NO:6) is provided herein.Type: ApplicationFiled: November 3, 2006Publication date: July 24, 2008Inventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Patent number: 7144569Abstract: A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, (ii) an epitope comprising sequence comprising: SEQ ID NO: 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (ii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognises the agent; recognition by the T cells indicating that the individual has, or is suType: GrantFiled: October 2, 2000Date of Patent: December 5, 2006Assignee: ISIS Innovation LimitedInventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Publication number: 20020136733Abstract: 8-11-Mer peptides are identified, from four Plasmodium falciparum antigens, circumsporozoite protein, thrombospondin-related anonymous protein, spirozoite hepatocyte binding antigen and liver-stage antigen-1, as actual or potential cytotoxic T lymphocyte epitopes for human leucocyte antigen class I molecules HLA-A2, HLA-B8, HA-B7 and HLA-B17. Vaccines for immunization against malaria contain these peptides or oligonucleotides coding for them. A method of inducing primary cytotoxic T lymphocyte responses to a chosen antigen or microorganism comprises incubating lymphocytes ex vivo with the chosen antigen or microorganism in the presence of keyhole limpet haemocyanin.Type: ApplicationFiled: January 11, 2002Publication date: September 26, 2002Inventors: Adrian Vivian Sinton Hill, Michael Aidoo, Catherine Elizabeth Margaret Allsopp, Ajit Lalvani, Magdalena Plebanski, Hilton Carter Whittle